Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELUDE: Pembrolizumab Plus Lenvatinib in Recurrent ccRCC
NCT07460206Phase 2Not yet recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Aug 2026
- Primary completion
- Aug 2031
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07460206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460206.